Find out how to deal online from £1.50 in a SIPP, ISA or Dealing Account.

Vectura Group Shares News & Articles

Market report: Fosun bid buoys Thomas Cook, Ferguson falls on quarterly sales miss

London’s FTSE 100 firms 43 points to 7,375 early on Monday as strong export data out of China and the reaching of a deal between the US and Mexico providing relief to markets rattled by President Donald Trump’s aggressive trade bargaining. Hard-pressed holidays company Thomas Cook (TCG) sparks up 23% to 19.8p as it confirms talks are underway with its largest shareholder, the Chinese group ...

Market report: GardaWorld walks away from G4S, Domino's down on overseas disappointment

US President Donald Trump’s latest trade war tariff threat weighs on sentiment on Tuesday, with the FTSE 100 cheapening 17.4 points to 7, 363.2. However, weakness among banks and utilities is being softened by strength among pharma and mining stocks and investors are perhaps taking some comfort in the news that China’s vice-premier Liu He will travel to the US for another round of trade talks ...

Market report: Next rallies on ‘in line’ Christmas sales but still cuts guidance as Apple issues profits shock

High street fashion chain Next (NXT) gets the eagerly awaited Christmas reporting season underway as it reports festive sales as expected but still lowers full year guidance. The UK retail sector has been under a cloud for weeks with investors anticipating a gloomy run-in to Christmas as consumers flex their muscles over discounts and on line bargains. Yet Next has survived the worst of the ...

Market report: Reckitt Benckiser down and Shire in more takeover disappointment

The FTSE 100 is up 23 points to 7,362.93 as tech heavy indices in the US and Asia weakened amid news of falling demand for smart phones. Cillit Bang maker Reckitt Benckiser (RB.) falls 4.8% to £55.28 after missing its first quarter growth estimates. To March 31, the company says that its Hygiene Home division which accounts for 38% of revenue was impacted by a difficult competitive market and ...

Hikma faces further delays in launching generic version of GlaxoSmithKline blockbuster drug

Hikma Pharmaceuticals (HIK) has been dealt another blow after US regulators said it had to conduct a further clinical study into its generic version of GlaxoSmithKline’s (GSK) Advair asthma treatment. The news has triggered a 1.8% decline in Hikma’s share price to 882p. Vectura (VEC) fell 7.2% to 75.4p as it is responsible for the dry powder technology for Hikma’s generic treatment. In ...
Showing 1 to 20 of 58